These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
96 related articles for article (PubMed ID: 15166480)
81. STAT1-deficient mice are resistant to cecal ligation and puncture-induced septic shock. Herzig D; Fang G; Toliver-Kinsky TE; Guo Y; Bohannon J; Sherwood ER Shock; 2012 Oct; 38(4):395-402. PubMed ID: 22777121 [TBL] [Abstract][Full Text] [Related]
82. Protein tyrosine kinase Pyk2 mediates the Jak-dependent activation of MAPK and Stat1 in IFN-gamma, but not IFN-alpha, signaling. Takaoka A; Tanaka N; Mitani Y; Miyazaki T; Fujii H; Sato M; Kovarik P; Decker T; Schlessinger J; Taniguchi T EMBO J; 1999 May; 18(9):2480-8. PubMed ID: 10228162 [TBL] [Abstract][Full Text] [Related]
83. The human papilloma virus (HPV)-18 E6 oncoprotein physically associates with Tyk2 and impairs Jak-STAT activation by interferon-alpha. Li S; Labrecque S; Gauzzi MC; Cuddihy AR; Wong AH; Pellegrini S; Matlashewski GJ; Koromilas AE Oncogene; 1999 Oct; 18(42):5727-37. PubMed ID: 10523853 [TBL] [Abstract][Full Text] [Related]
84. Requirement for STAT1 in LPS-induced gene expression in macrophages. Ohmori Y; Hamilton TA J Leukoc Biol; 2001 Apr; 69(4):598-604. PubMed ID: 11310846 [TBL] [Abstract][Full Text] [Related]
85. Control of Leishmania major in the absence of Tyk2 kinase. Schleicher U; Mattner J; Blos M; Schindler H; Röllinghoff M; Karaghiosoff M; Müller M; Werner-Felmayer G; Bogdan C Eur J Immunol; 2004 Feb; 34(2):519-29. PubMed ID: 14768057 [TBL] [Abstract][Full Text] [Related]
86. Synthesis of alpha-chemokines IP-10, I-TAC, and MIG are differentially regulated in human corneal keratocytes. McInnis KA; Britain A; Lausch RN; Oakes JE Invest Ophthalmol Vis Sci; 2005 May; 46(5):1668-74. PubMed ID: 15851567 [TBL] [Abstract][Full Text] [Related]
87. Tyk2 is essential for IFN-alpha-induced gene expression in mast cells. Mori Y; Hirose K; Suzuki K; Nakajima H; Seto Y; Ikeda K; Shimoda K; Nakayama K; Saito Y; Iwamoto I Int Arch Allergy Immunol; 2004 Jun; 134 Suppl 1():25-9. PubMed ID: 15166480 [TBL] [Abstract][Full Text] [Related]
88. Therapeutic Advantage of Tyk2 Inhibition for Treating Autoimmune and Chronic Inflammatory Diseases. Muromoto R; Shimoda K; Oritani K; Matsuda T Biol Pharm Bull; 2021; 44(11):1585-1592. PubMed ID: 34719635 [TBL] [Abstract][Full Text] [Related]